Somaxon Pharmaceuticals Announces Silenor® Co-Promotion Agreement With Procter & Gamble
Somaxon Pharmaceuticals, Inc. today announced that Somaxon and Procter & Gamble have entered into a co-promotion agreement for Silenor (doxepin), a newly-approved treatment for insomnia characterized by difficulty with sleep maintenance.
Read more...
Press Release
Somaxon Pharmaceuticals Inc. Posted on:25 Aug 10 Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX) today announced that Somaxon and Procter & Gamble (NYSE:PG) have entered into a co-promotion agreement for Silenor® (doxepin), a newly-approved treatment for insomnia characterized by difficulty with sleep maintenance.
Read more...
Statement from Eli Lilly and Company Regarding Approval Recommendation from FDA Advisory Committee for Expanding the ...
BETHESDA, Md., Aug. 19 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) Anesthetic and Life Support Drugs Advisory Committee voted today 8-6 in favor of expanding the pain indications for Eli Lilly and Company's (NYSE: LLY) Cymbalta® (duloxetine HCl) to a broader pain population that will be further defined by the FDA, if approved. The committee reviewed efficacy and safety ...
Read more...
Kevin Niksarli, M.D. Of Newsight Laser Center, New York, N.Y. Reminds Early Detection Critical to Slowing Progress of Glaucoma on 6/17/2009
New York, NY (PRWEB) June 20, 2009 -- http://www.newsightlaser.com/ [Kevin Niksarli, M.D. __title__ newsightlaser.com] of http://www.newsightlaser.com/ [Newsight Laser Center __title__...
Read more...
Achoo! Ragweed Season Is Here - WebMD (blog)
Read more...
|